相关实验视频

Updated: Jun 4, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

治疗壮症诱导的糖尿病:一个更新的提案

Betina Biagetti¹, Marta Araujo-Castro^2,3, Mónica Marazuela⁴

¹Endocrinology & Nutrition Department, Hospital Universitario Vall de Hebrón. CIBERER U747 (ISCIII), ENDO-ERN, Barcelona, Spain. betinaloys.biagetti@vallhebron.cat.

|December 31, 2024

概括

由于生长激素 (GH) 和胰岛素类生长因子1 (IGF-1) 的过量,壮症诱导的糖尿病需要专门的管理. 针对独特的代谢特征和并发症的整体治疗对于最佳结果至关重要.

科学领域:

内分泌学在内分泌学.
代谢障碍代谢障碍代谢障碍
药理学药理学是指药理学的学科.

背景情况:

壮症诱导的糖尿病具有独特的特征,包括胰岛素耐药性,低体脂和水分保留,由多余的生长激素 (GH) 和类似胰岛素的生长因子1 (IGF-1) 驱动.
这种情况显著增加了心血管风险,需要与经典的2型糖尿病不同的管理.

研究的目的:

为了突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出
讨论最佳管理策略,包括同时控制GH过分泌和考虑药物特定的代谢效应.
评估新药类在管理这种复杂疾病中的作用.

主要方法:

综述壮症诱导糖尿病的病理生理学.
分析当前和新兴的药理疗法用于糖尿病在壮病患者.
考虑特定药物的代谢影响和壮病独特的代谢特征.

主要成果:

有效的管理需要控制碳水化合物干扰和GH过分分泌.
甲胺是一种具有成本效益的第一线治疗方法.
像GLP-1RA和SGLT-2抑制剂这样的较新的药物显示出有前途,但需要仔细考虑积病的特定代谢特征,包括增强的性状态和对GH分泌的隐形素影响.

结论:

综合性治疗方法对于治疗壮症诱导的糖尿病至关重要,包括治疗并发症的药物.
了解不同的病理生理学和新药类的好处对于优化患者的治疗结果和生活质量至关重要.

关键词:

壮成长是一种壮成长.糖尿病糖尿病糖尿病这就是GLP-1.准则准则准则准则过高血糖症的发生.这就是SGLT2i.

更多相关视频

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

相关概念视频

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...